|
ANKRD52 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.3183999447719E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.80350000384055E-08 |
| Normal-vs-Stage2 |
4.880500E-03 |
| Normal-vs-Stage3 |
6.29730001477924E-09 |
| Normal-vs-Stage4 |
2.35209962617944E-10 |
| Stage1-vs-Stage2 |
1.190790E-01 |
| Stage1-vs-Stage3 |
3.450200E-01 |
| Stage1-vs-Stage4 |
2.143700E-02 |
| Stage2-vs-Stage3 |
3.739800E-02 |
| Stage2-vs-Stage4 |
5.762400E-03 |
| Stage3-vs-Stage4 |
2.192400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.49700000068509E-08 |
| Normal-vs-AfricanAmerican |
3.020800E-04 |
| Normal-vs-Asian |
7.13659999984628E-07 |
| Caucasian-vs-AfricanAmerican |
7.386000E-01 |
| Caucasian-vs-Asian |
7.525800E-01 |
| AfricanAmerican-vs-Asian |
6.245800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.52819998269871E-09 |
| Normal-vs-Female |
1.31189999974524E-08 |
| Male-vs-Female |
3.260400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.02349995145801E-09 |
| Normal-vs-Age(41-60Yrs) |
1.51439999984682E-07 |
| Normal-vs-Age(61-80Yrs) |
6.25020002420484E-09 |
| Normal-vs-Age(81-100Yrs) |
2.156300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.238600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.790600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.908400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.268200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.171400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.784600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.102800E-03 |
| Classical-VS-Follicular |
4.011000E-01 |
| Classical-VS-Other |
7.525800E-02 |
| Classical-VS-Normal |
1.71739999998977E-08 |
| Tall-VS-Follicular |
1.025830E-01 |
| Tall-VS-Other |
6.723600E-01 |
| Tall-VS-Normal |
2.26259999625E-08 |
| Follicular-VS-Other |
3.248600E-01 |
| Follicular-VS-Normal |
3.00779999995449E-06 |
| Other-VS-Normal |
3.619900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55009999946998E-07 |
| Normal-vs-N1 |
1.41720002400092E-09 |
| N0-vs-N1 |
3.522000E-02 |
|
|
